Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute Licenses CRISPR-Cas9 Technology to Promega

NEW YORK (GenomeWeb) – Promega said today that it has non-exclusively licensed the Broad Institute's CRISPR-Cas9 intellectual property.

Under the terms of the agreement, Promega will combine the Broad's CRISPR-Cas9 technology with its own products for knock-in of genetic reporters into the genomes of any cell or cell line. The firm is aiming to develop and sell gene editing tools and reagents for interrogating endogenous biology at physiologically relevant expression levels.

Financial terms of the deal were not disclosed.

"With this combination of CRISPR and our most advanced reporter technologies like HiBiT, we are able to look at the dynamics of endogenous proteins in real time with unprecedented ease and sensitivity," Promega Senior Research Scientist Thomas Machleidt said in a statement.

Promega noted that a 2017 paper published in ACS Chemical Biology showed that the Promega HiBiT Protein Tagging System can be combined with CRISPR-Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions. A more recent paper in the same journal described a strategy for monitoring the degradation of endogenously tagged HiBiT-BET family members in live cells.

The Broad has made several licensing deals for its CRISPR IP over the past several months, most recently last October with Cambridge, UK-based human cell products provider DefiniGen for the development of human cell disease models.